Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T.

N Engl J Med. 1995 Apr 27;332(17):1132-6.

2.
3.

The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.

Treliński J, Tybura M, Smolewski P, Robak T, Chojnowski K.

Blood Coagul Fibrinolysis. 2009 Dec;20(8):646-51. doi: 10.1097/MBC.0b013e32832f6c5b.

PMID:
19741509
4.

Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.

Sagripanti A, Ferretti A, Nicolini A, Carpi A.

Biomed Pharmacother. 1996;50(8):376-82.

PMID:
8952859
5.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T; GIMEMA CMD-Working Party.

Haematologica. 2008 Mar;93(3):372-80. doi: 10.3324/haematol.12053. Epub 2008 Feb 11.

6.
7.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.

N Engl J Med. 2005 Jul 7;353(1):33-45.

8.

Acute coronary disease in essential thrombocythemia and polycythemia vera.

Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A.

J Intern Med. 1998 Jul;244(1):49-53.

9.

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.

Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T.

Ann Hematol. 2001 Feb;80(2):74-8.

PMID:
11261328
10.

Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses.

García-Rinaldi R, Carro-Pagán C, Schaff HV, McKellar SH, Thompson JL 3rd, Quiñones J, Rodríguez-Acosta JF.

J Heart Valve Dis. 2009 Nov;18(6):617-25; discussion 626.

PMID:
20099710
11.

Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?

Ruggeri M, Castaman G, Rodeghiero F.

Haematologica. 1993 Nov-Dec;78(6 Suppl 2):18-21.

PMID:
8039753
12.
13.

Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.

Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:47-56. Review.

PMID:
8951772
15.

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE.

N Engl J Med. 1998 Dec 3;339(23):1665-71.

17.

Clinical course of essential thrombocythemia in 147 cases.

Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F.

Cancer. 1990 Aug 1;66(3):549-56.

18.

Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.

Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A.

Hematol Oncol. 2007 Sep;25(3):115-20.

PMID:
17464935
19.

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.

Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, Kho BC, Lee HK, Sim JP, Chan CH, Chan JC, Yeung YM, Law M, Liang R.

Arch Intern Med. 2005 Dec 12-26;165(22):2651-8.

PMID:
16344424
20.

Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.

Randi ML, Rossi C, Fabris F, Menapace L, Girolami A.

Clin Appl Thromb Hemost. 1999 Apr;5(2):131-5.

PMID:
10725994

Supplemental Content

Support Center